BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND DDX3X, DDX14, 1654, ENSG00000215301, DBX, DDX3, HLP2 AND Prognosis
15 results:

  • 1. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
    Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
    BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Full-spectral genome analysis of natural killer/T cell lymphoma highlights impacts of genome instability in driving its progression.
    Chen Z; Huang H; Hong H; Huang H; Weng H; Yu L; Xiao J; Wang Z; Fang X; Yao Y; Yue JX; Lin T
    Genome Med; 2024 Apr; 16(1):48. PubMed ID: 38566223
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Establishment of ganglioside GD2-expressing extranodal NK/T-cell lymphoma cell line with scRNA-seq analysis.
    Sato S; Ishii M; Tachibana K; Furukawa Y; Toyota T; Kinoshita S; Azusawa Y; Ando J; Ando M
    Exp Hematol; 2024 Feb; 130():104132. PubMed ID: 38029851
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
    Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
    Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of ddx3x-TP53.
    Gao F; Hu K; Zheng P; Shi H; Ke X
    Cancer Med; 2023 May; 12(9):10267-10279. PubMed ID: 36971051
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.
    Cai J; Liu P; Huang H; Li Y; Ma S; Zhou H; Tian X; Zhang Y; Gao Y; Xia Y; Zhang X; Yang H; Li L; Cai Q
    Signal Transduct Target Ther; 2020 Dec; 5(1):289. PubMed ID: 33376237
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Failure of tofacitinib to achieve an objective response in a
    Wong J; Wall M; Corboy GP; Taubenheim N; Gregory GP; Opat S; Shortt J
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843425
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. CD56-positive diffuse large B-cell lymphoma/leukemia with
    Liu Y; Shen J; Awal Issah M; Liu T; Zhou H; Fu H
    J Int Med Res; 2020 May; 48(5):300060520918087. PubMed ID: 32363958
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.
    Montes-Mojarro IA; Chen BJ; Ramirez-Ibarguen AF; Quezada-Fiallos CM; Pérez-Báez WB; Dueñas D; Casavilca-Zambrano S; Ortiz-Mayor M; Rojas-Bilbao E; García-Rivello H; Metrebian MF; Narbaitz M; Barrionuevo C; Lome-Maldonado C; Bonzheim I; Fend F; Steinhilber J; Quintanilla-Martinez L
    Mod Pathol; 2020 May; 33(5):781-791. PubMed ID: 31822801
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.
    Ramis-Zaldivar JE; Gonzalez-Farré B; Balagué O; Celis V; Nadeu F; Salmerón-Villalobos J; Andrés M; Martin-Guerrero I; Garrido-Pontnou M; Gaafar A; Suñol M; Bárcena C; Garcia-Bragado F; Andión M; Azorín D; Astigarraga I; Sagaseta de Ilurdoz M; Sábado C; Gallego S; Verdú-Amorós J; Fernandez-Delgado R; Perez V; Tapia G; Mozos A; Torrent M; Solano-Páez P; Rivas-Delgado A; Dlouhy I; Clot G; Enjuanes A; López-Guillermo A; Galera P; Oberley MJ; Maguire A; Ramsower C; Rimsza LM; Quintanilla-Martinez L; Jaffe ES; Campo E; Salaverria I
    Blood; 2020 Jan; 135(4):274-286. PubMed ID: 31738823
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Somatic mutations in
    Gao LM; Zhao S; Zhang WY; Wang M; Li HF; Lizaso A; Liu WP
    Cancer Biol Ther; 2019; 20(10):1319-1327. PubMed ID: 31311407
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Frequent Mutations in Natural Killer/T Cell lymphoma.
    Zhang Y; Li C; Xue W; Zhang M; Li Z
    Cell Physiol Biochem; 2018; 49(1):1-16. PubMed ID: 30134235
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
    Dufva O; Kankainen M; Kelkka T; Sekiguchi N; Awad SA; Eldfors S; Yadav B; Kuusanmäki H; Malani D; Andersson EI; Pietarinen P; Saikko L; Kovanen PE; Ojala T; Lee DA; Loughran TP; Nakazawa H; Suzumiya J; Suzuki R; Ko YH; Kim WS; Chuang SS; Aittokallio T; Chan WC; Ohshima K; Ishida F; Mustjoki S
    Nat Commun; 2018 Apr; 9(1):1567. PubMed ID: 29674644
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Exome sequencing identifies somatic mutations of ddx3x in natural killer/T-cell lymphoma.
    Jiang L; Gu ZH; Yan ZX; Zhao X; Xie YY; Zhang ZG; Pan CM; Hu Y; Cai CP; Dong Y; Huang JY; Wang L; Shen Y; Meng G; Zhou JF; Hu JD; Wang JF; Liu YH; Yang LH; Zhang F; Wang JM; Wang Z; Peng ZG; Chen FY; Sun ZM; Ding H; Shi JM; Hou J; Yan JS; Shi JY; Xu L; Li Y; Lu J; Zheng Z; Xue W; Zhao WL; Chen Z; Chen SJ
    Nat Genet; 2015 Sep; 47(9):1061-6. PubMed ID: 26192917
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
    Briones J; Novelli S; García-Marco JA; Tomás JF; Bernal T; Grande C; Canales MA; Torres A; Moraleda JM; Panizo C; Jarque I; Palmero F; Hernández M; González-Barca E; López D; Caballero D;
    Haematologica; 2014 Mar; 99(3):505-10. PubMed ID: 24162789
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.